{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:02:30Z","timestamp":1784138550958,"version":"3.55.0"},"reference-count":41,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Currently, no rabies virus-specific antiviral drugs are available. Ranpirnase has strong antitumor and antiviral properties associated with its ribonuclease activity. TMR-001, a proprietary bulk drug substance solution of ranpirnase, was evaluated against rabies virus in three cell types: mouse neuroblastoma, BSR (baby hamster kidney cells), and bat primary fibroblast cells. When TMR-001 was added to cell monolayers 24 h preinfection, rabies virus release was inhibited for all cell types at three time points postinfection. TMR-001 treatment simultaneous with infection and 24 h postinfection effectively inhibited rabies virus release in the supernatant and cell-to-cell spread with 50% inhibitory concentrations of 0.2\u20132 nM and 20\u2013600 nM, respectively. TMR-001 was administered at 0.1 mg\/kg via intraperitoneal, intramuscular, or intravenous routes to Syrian hamsters beginning 24 h before a lethal rabies virus challenge and continuing once per day for up to 10 days. TMR-001 at this dose, formulation, and route of delivery did not prevent rabies virus transit from the periphery to the central nervous system in this model (n = 32). Further aspects of local controlled delivery of other active formulations or dose concentrations of TMR-001 or ribonuclease analogues should be investigated for this class of drugs as a rabies antiviral therapeutic.<\/jats:p>","DOI":"10.3390\/v12020177","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T02:59:18Z","timestamp":1580957958000},"page":"177","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antiviral Ranpirnase TMR-001 Inhibits Rabies Virus Release and Cell-to-Cell Infection In Vitro"],"prefix":"10.3390","volume":"12","author":[{"given":"Todd G.","family":"Smith","sequence":"first","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix R.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint N.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Carson","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock E.","family":"Martin","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Gallardo-Romero","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-4857","authenticated-orcid":false,"given":"James A.","family":"Ellison","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-1952","authenticated-orcid":false,"given":"Lauren","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hodge","sequence":"additional","affiliation":[{"name":"Tamir Biotechnology, Inc. 12625 High Bluff Drive Suite 113, San Diego, CA 92130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Squiquera","sequence":"additional","affiliation":[{"name":"Tamir Biotechnology, Inc. 12625 High Bluff Drive Suite 113, San Diego, CA 92130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Sulley","sequence":"additional","affiliation":[{"name":"Tamir Biotechnology, Inc. 12625 High Bluff Drive Suite 113, San Diego, CA 92130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-7680","authenticated-orcid":false,"given":"Victoria A.","family":"Olson","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Hutson","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: Recommendations of the advisory committee on immunization practices","volume":"59","author":"Rupprecht","year":"2010","journal-title":"MMWR Recomm. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., Barrat, J., Blanton, J.D., Briggs, D.J., and Cleaveland, S. (2015). Global Alliance for Rabies Control Partners for Rabies Prevention. Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003786"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11908-012-0268-2","article-title":"Rabies: Still a uniformly fatal disease? Historical occurrence, epidemiological trends, and paradigm shifts","volume":"14","author":"Feder","year":"2012","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1056\/NEJMoa050382","article-title":"Survival after treatment of rabies with induction of coma","volume":"352","author":"Willoughby","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2851","article-title":"Antiviral therapy for human rabies","volume":"20","author":"Appolinario","year":"2015","journal-title":"Antivir. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1016\/j.vaccine.2017.12.051","article-title":"The path towards effective antivirals against rabies","volume":"37","author":"Jochmans","year":"2019","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0021-9258(18)52427-3","article-title":"Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases","volume":"266","author":"Ardelt","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_8","first-page":"169","article-title":"Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent","volume":"21","author":"Darzynkiewicz","year":"1988","journal-title":"Cell Tissue Kinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.leu.2401100","article-title":"G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1\/CIP1 and p27KIP and decreased pRb phosphorylation","volume":"12","author":"Juan","year":"1998","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/mcbr.2000.0266","article-title":"Differential requirement for the stress-activated protein kinase\/c-Jun NH(2)-terminal kinase in RNAdamage-induced apoptosis in primary and in immortalized fibroblasts","volume":"4","author":"Iordanov","year":"2000","journal-title":"Mol. Cell. Biol. Res. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1200\/JCO.2002.20.1.274","article-title":"Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma","volume":"20","author":"Mikulski","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_12","first-page":"577a","article-title":"Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (pts) with unresectable malignant mesothelioma (UMM): Analysis of survival","volume":"19","author":"Vogelzang","year":"2000","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"ref_13","first-page":"601","article-title":"Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma","volume":"2","author":"Porta","year":"2008","journal-title":"Biologics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14712598.6.4.391","article-title":"Ranpirnase\u2014An antitumour ribonuclease: Its potential role in malignant mesothelioma","volume":"6","author":"Pavlakis","year":"2006","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3851\/IMP3133","article-title":"Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study","volume":"22","author":"Squiquera","year":"2017","journal-title":"Antivir. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1074\/jbc.271.34.20783","article-title":"Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease","volume":"271","author":"Saxena","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1089\/aid.2017.0308","article-title":"Ranpirnase Reduces HIV-1 Infection and Associated Inflammatory Changes in a Human Colorectal Explant Model","volume":"34","author":"Brand","year":"2018","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.antiviral.2016.06.009","article-title":"Antiviral effect of ranpirnase against Ebola virus","volume":"132","author":"Hodge","year":"2016","journal-title":"Antiviral Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.18632\/oncotarget.14302","article-title":"Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase","volume":"8","author":"Vert","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"10686","DOI":"10.1016\/S0021-9258(18)82252-9","article-title":"A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity","volume":"268","author":"Wu","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_21","first-page":"1983","article-title":"Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis","volume":"60","author":"Iordanov","year":"2000","journal-title":"Cancer Res."},{"key":"ref_22","first-page":"11","article-title":"Potentiation of tumor necrosis factor induced apoptosis by onconase","volume":"13","author":"Deptala","year":"1998","journal-title":"Int. J. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E861","DOI":"10.1073\/pnas.1210198110","article-title":"Host-rabies virus protein-protein interactions as druggable antiviral targets","volume":"110","author":"Lingappa","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Smith, T.G., and Gilbert, A.T. (2017). Comparison of a Micro-Neutralization Test with the Rapid Fluorescent Focus Inhibition Test for Measuring Rabies Virus Neutralizing Antibodies. Trop. Med. Infect. Dis., 2.","DOI":"10.3390\/tropicalmed2030024"},{"key":"ref_26","unstructured":"Meslin, F.X., Kaplan, M.M., and Koprowski, H. (1996). The fluorescent antibody test. Laboratory Techniques in Rabies, World Health Organization. [4th ed.]."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/13.6.515","article-title":"Ribonuclease activity of peripheral leucocytes and serum in rabies-susceptible and rabies-refractory mice","volume":"13","author":"Enright","year":"1965","journal-title":"J. Histochem. Cytochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1016\/j.vaccine.2009.09.034","article-title":"Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines","volume":"27","author":"Franka","year":"2009","journal-title":"Vaccine"},{"key":"ref_29","first-page":"41","article-title":"Antiviral activity of Bacillus intermedius RNAase in guinea-pigs and rabbits infected with outdoor rabies virus","volume":"51","author":"Gribencha","year":"2006","journal-title":"Vopr. Virusol."},{"key":"ref_30","first-page":"4180","article-title":"Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily","volume":"56","author":"Vasandani","year":"1996","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1523\/JNEUROSCI.14-02-00538.1994","article-title":"Toxicity of an antitumor ribonuclease to Purkinje neurons","volume":"14","author":"Newton","year":"1994","journal-title":"J. Neurosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1016\/j.vaccine.2017.12.028","article-title":"Mannitol treatment is not effective in therapy of rabies virus infection in mice","volume":"37","author":"Dufkova","year":"2019","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0168-3659(98)00091-1","article-title":"Monoacylation of ribonuclease A enables its transport across an in vitro model of the blood-brain barrier","volume":"56","author":"Chopineau","year":"1998","journal-title":"J. Control. Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1158\/1535-7163.MCT-10-0338","article-title":"Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells","volume":"9","author":"Chang","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_36","unstructured":"(2018, September 20). Bat Rabies Outbreak in Peru Claims One, but Others Survive: Mass Vaccination Campaign Underway. Available online: https:\/\/rabiesalliance.org\/resource\/bat-rabies-outbreak-peru-claims-one-others-survive-mass-vaccination-campaign-underway."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1016\/j.vaccine.2017.10.109","article-title":"Re-evaluating the effect of Favipiravir treatment on rabies virus infection","volume":"37","author":"Banyard","year":"2019","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1016\/j.vaccine.2018.05.066","article-title":"Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin","volume":"37","author":"Marosi","year":"2019","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1016\/j.vaccine.2018.01.082","article-title":"Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication","volume":"37","author":"Marosi","year":"2019","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104641","DOI":"10.1016\/j.antiviral.2019.104641","article-title":"Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis","volume":"172","author":"Yamada","year":"2019","journal-title":"Antiviral Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1016\/j.vaccine.2018.01.066","article-title":"Dermaseptins as potential antirabies compounds","volume":"37","author":"Mechlia","year":"2019","journal-title":"Vaccine"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/2\/177\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:54:43Z","timestamp":1760172883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/2\/177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["v12020177"],"URL":"https:\/\/doi.org\/10.3390\/v12020177","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]}}}